J&J Looks To Expand Consumer Business After Consent Decree Obligations End
This article was originally published in The Tan Sheet
Executive Summary
J&J is “very excited about the possibility of consumer becoming a bigger part of our business,” CFO Caruso says, noting it hopes to grow the business organically and through acquisitions. But J&J first must complete its obligations under a consent decree related to manufacturing quality problems.
You may also be interested in...
J&J Bit Off More Than McNeil Could Chew In 2006 Pfizer OTC Acquisition
McNeil scaled up its manufacturing “volume and complexity substantially” following J&J’s acquisition of Pfizer’s consumer business in 2006, says McNeil Consumer VP Shane Freedman. “Just a few years later, we had the recalls” that led eventually to a consent decree with FDA,” he says.
J&J Bit Off More Than McNeil Could Chew In 2006 Pfizer OTC Acquisition
McNeil scaled up its manufacturing “volume and complexity substantially” following J&J’s acquisition of Pfizer’s consumer business in 2006, says McNeil Consumer VP Shane Freedman. “Just a few years later, we had the recalls” that led eventually to a consent decree with FDA,” he says.
J&J Bit Off More Than McNeil Could Chew In 2006 Pfizer OTC Acquisition
McNeil scaled up its manufacturing “volume and complexity substantially” following J&J’s acquisition of Pfizer’s consumer business in 2006, says McNeil Consumer VP Shane Freedman. “Just a few years later, we had the recalls” that led eventually to a consent decree with FDA,” he says.